SM
ITCI

Sabby Management’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Sabby Management’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-148
Closed -$226K – 333
2016
Q3 		$226K Sell
148
-1,319
-90% -$53.3K 0.01% 271
2016
Q2 		$5.7M Buy
1,467
+259
+21% +$9.31K 0.3% 50
2016
Q1 		$3.36M Buy
1,208
+688
+132% +$22.9K 0.17% 63
2015
Q4 		$2.8M Buy
+520
New +$26.2K 0.15% 99

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $34.9B AUM 72.7% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SC
Samlyn Capital New York $6.14B AUM 42.05% 1-Year Est. Return

Sabby Management's ITCI Position: Q1 2021 in Review

Sabby Management sold out of Intra-Cellular Therapies Inc. (ITCI) in Q1 2021, closing a stake of 35,000 shares — an estimated $1.11M sold.

Sabby Management first reported a position in ITCI in Q1 2015 and held it in 6 quarters. The position peaked at $2.95M in Q3 2020. 170 funds tracked by Wall St. Rank hold ITCI as of Q1 2021.

  • Sabby Management reported no remaining Intra-Cellular Therapies Inc. position as of Q1 2021 after selling out during the quarter.
  • Sabby Management sold 35,000 Intra-Cellular Therapies Inc. shares in Q1 2021, an estimated $1.11M.
  • Sabby Management first reported a position in Intra-Cellular Therapies Inc. in Q1 2015 and held it in 6 quarters.
  • Sabby Management's Intra-Cellular Therapies Inc. position peaked at $2.95M in Q3 2020.
  • 170 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q1 2021.

Based on Sabby Management's 13F filing for Q1 2021, filed 17 May 2021.